NICE has said Biogen's Tysabri can now be used by the NHS in England and Wales to treat highly active relapsing-remitting ...

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which has upheld the company's patent protection ...

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept Therapeutics with a ...

Denmark's Genmab has decided not to continue the development of a drug for cancer, acasunlimab, which had reached phase 3 testing, after a review of its medicines pipeline. The decision to end the ...

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an initial public offering (IPO) in Hong ...

Equip health professionals with resources to diagnose and treat conditions across all skin tones. Make mental health support ...

Shares in Ultragenyx and Mereo BioPharma have plunged after their drug for osteogenesis imperfecta (OI) or brittle bone ...

Judge Lance Walker sided with the American Hospital Association (AHA) and other plaintiffs in the lawsuit, brought in a Maine ...

The NHS has an extraordinary opportunity in 2026. Unified data, decision intelligence, and strong workforce capability can ...

Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Newland, CEO of ANGLE, about why live cell liquid ...

In 2026, we will see widespread adoption of AI tools that automate time-consuming administrative tasks: drafting clinical ...